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Plasmacytoid Precursor Dendritic Cells From NOD Mice
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Are They a Component of Diabetes Pathogenesis?
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Paula M. Chilton, and Suzanne T. Ildstad
OBJECTIVE—Plasmacytoid precursor dendritic cell facilitating
cells (p-preDC FCs) play a critical role in facilitation of syngeneic
and allogeneic hematopoietic stem cell (HSC) engraftment. Here,
we evaluated the phenotype and function of CD8
/TCR
 FCs
from NOD mice.
RESEARCH DESIGN AND METHODS—The phenotype of
CD8
/TCR
 FCs was analyzed by ﬂow cytometry using sorted
FCs from NOD, NOR, or B6 mice. The function of NOD FCs was
evaluated by colony-forming cell (CFC) assay in vitro and
syngeneic or allogeneic HSC transplantation in vivo.
RESULTS—We report for the ﬁrst time that NOD FCs are
functionally impaired. They fail to facilitate engraftment of
syngeneic and allogeneic HSCs in vivo and do not enhance HSC
clonogenicity in vitro. NOD FCs contain subpopulations similar
to those previously described in B6 FCs, including p-preDC,
CD19
, NK1.1
DX5
, and myeloid cells. However, the CD19

and NK1.1
DX5
 subpopulations are signiﬁcantly decreased in
number in NOD FCs compared with disease-resistant controls.
Removal of the CD19
 or NK1.1
DX5
 subpopulations from FCs
did not signiﬁcantly affect facilitation. Notably, Flt3 ligand (FL)
treatment of NOD donors expanded FC total in peripheral blood
and restored facilitating function in vivo.
CONCLUSIONS—These data demonstrate that NOD FCs ex-
hibit signiﬁcantly impaired function that is reversible, since FL
restored production of functional FCs in NOD mice and suggest
that FL plays an important role in the regulation and develop-
ment of FC function. FCs may therefore be linked to diabetes
pathogenesis and prevention. Diabetes 57:2360–2370, 2008
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e were the ﬁrst to identify a CD8
/TCR

facilitating cell (FC) population in mouse
bone marrow that facilitates hematopoietic
stem cell (HSC) engraftment across major
histocompatibility complex (MHC) barriers without caus-
ing graft-versus-host disease (GVHD) (1–3). FCs are a
heterogeneous cell population, with the predominant sub-
population resembling B220
/CD11c
/CD11b
 plasmacy-
toid precursor dendritic cells (p-preDC) (4). p-preDC FCs
display characteristic plasmacytoid morphology and pro-
duce interferon (IFN)-, tumor necrosis factor (TNF)-,
and other cytokines in response to CpG-oligodeoxynucle-
otides (CpG-ODN) (4). p-preDC FCs also have the capacity
to differentiate into mature dendritic cells (DCs) by up-
regulating MHC class II, CD86, and CD80 activation mark-
ers (4). Removal of p-preDC FCs completely abrogates
facilitation, suggesting that p-preDC FCs play a critical
role in facilitation (4).
NOD mice develop spontaneous autoimmune diabetes
due to defects in both peripheral and central tolerance
mechanisms (5). Several regulatory defects have been
described in NOD mice, including islet-reactive T-cells that
escape deletion, impaired generation of regulatory T-cells
(Treg), inhibitory cytokines, aberrant professional antigen-
presenting cell (APC) function, and low levels of NK cell
activity (6,7). B-cells also contribute to the development of
diabetes in NOD mice in their role as professional APCs
(8). The role of p-preDC in pathogenesis of autoimmune
disease has been addressed (9). Several groups reported
abnormalities in DC phenotype and function in human
type 1 diabetes and NOD mice (10,11). An understanding
of which speciﬁc DC subsets play a critical role in main-
tenance of self-tolerance and prevention of diabetes may
allow novel cell-based therapies to be used in the clinic for
disease prevention.
In the present study, we evaluated the phenotype and
function of NOD FCs. We report for the ﬁrst time that NOD
FCs are functionally impaired in vivo and in vitro. As in
disease-resistant controls, the B220
/CD11c
/CD11b
 p-
preDC FC subpopulation represents the major subpopula-
tion of CD8
/TCR
 FCs in NOD bone marrow. The CD19

or NK1.1
DX5
 FC subpopulations were signiﬁcantly de-
creased in NOD FCs compared with those from B6 or
MHC-congenic diabetes-resistant NOR mice (12). NOR
FCs signiﬁcantly enhanced engraftment of NOR HSCs.
In striking contrast, NOD FCs were completely impaired
in function and did not facilitate HSC engraftment.
Similarly, NOD FCs were impaired in function in vitro.
NOR p-preDC FCs were more efﬁcient at granulocyte-
macrophage colony-stimulating factor (GM-CSF), inter-
leukin (IL)-6, macrophage inﬂammatory protein (MIP)-
1/CCL3, Rantes/CCL5, and TNF- production in
response to CpG compared with NOD p-preDC FCs.
Removal of the CD19
 or NK1.1
DX5
 FC subpopula-
tions did not signiﬁcantly impair facilitation. Notably,
FL treatment of NOD mice expanded FCs in peripheral
blood (PB), and these FL-PB-FCs signiﬁcantly enhanced
engraftment of HSCs. The fact that FL treatment re-
stored the function of NOD FCs suggests that FL may
represent a key cytokine for the development and
function of FCs. FCs may therefore be a critical link in
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2360 DIABETES, VOL. 57, SEPTEMBER 2008diabetes pathogenesis and prevention and may provide
a novel cell-based approach to restore self-tolerance
and regulation in treatment of type 1 diabetes.
RESEARCH DESIGN AND METHODS
Mice. Four- to six-week-old NOD mice (male and female; Taconic Laborato-
ries, Germantown, NY), female nonobese resistant (NOR) mice, male C57BL/6
mice, and female C57BL/10SnJ mice (Jackson Laboratory, Bar Harbor, ME)
were used. Animals were housed in the barrier facility at the Institute for
Cellular Therapeutics (Louisville, KY) and were cared for according to
National Institutes of Health animal care guidelines.
Antibodies. All monoclonal antibodies (mAbs) used in this study were
purchased from BD Biosciences (San Diego, CA). c-Kit
Sca-1
Lin
 (HSC)
sorting experiments used the following mAbs: stem cell antigen-1 (Sca-1)
phycoerythrin (PE), c-Kit allophycocyanin (APC), and the lineage panel
consisting of the following: CD8 ﬂuorescein isothiocyanate (FITC), Mac-1
FITC, B220 FITC, Gr-1 FITC, -TCR FITC, and -TCR FITC. CD8
/TCR
 FC
sorting experiments used -TCR FITC, -TCR FITC, and CD8 PE. CD8
/
TCR
/CD19
 sorting experiments used CD8 PE, -TCR FITC, -TCR FITC,
and CD19 APC. CD8
/TCR
/NK1.1
DX5
 cells were sorted by using CD8
APC, -TCR FITC, -TCR FITC, NK1.1 PE, and DX5 PE.
Sorting of HSCs and FCs. HSCs and FCs were isolated from bone marrow
by multiparameter, live sterile cell sorting (FACSVantage SE; Becton Dickin-
son, Mountainview, CA), as previously described (4). Brieﬂy, bone marrow
was isolated and collected in a single cell suspension at a concentration of
100  10
6 cells/ml in sterile cell sort media, containing sterile 1 Hank’s
balanced salt solution without phenol red, 2% heat-inactivated fetal bovine
serum, 10 mmol  l
1  ml
1 HEPES buffer, and 30 l/ml gentamicin (Gibco,
Grand Island, NY). Directly labeled mAbs were added at saturating concen-
trations, and the cells were incubated for 30 min and washed with cell sort
media.
Phenotypic analysis of sorted CD8
/TCR
 FCs. Sorted FCs (purity was
95%) were incubated with Fc receptor block (anti-CD16/CD32) before
staining with lineage-speciﬁc markers: anti-CD11 FITC, CD11b APC, CD14
FITC, NK1.1 FITC, DX5 FITC, B220 PerCP, Gr-1 APC, and CD19 APC, as
previously described (4). Sorted FCs were analyzed for p-preDC FCs as
B220
/CD11c
/CD11b
 using Cell Quest Software (Becton Dickinson).
DC maturation and cytokine production. FCs were cultured alone or with
1 mol/l TLR-9 ligand CpG-ODN 1668 (TCCATGACGTTCCGATGCT) (Gibco
BRL Custom Primers) (13) for 18 h. Supernatants were assayed for cytokines
by Linco Diagnostic (St Charles, MO) using LINCOplex Multiplex immunoas-
say, and cells were stained with anti-CD80, anti-CD86, or anti-MHC class II
I-A
d (39-10-8) FITC mAbs, with appropriately matched isotype controls.
HSC and/or FC transplantation. In the syngeneic model, recipients were
conditioned with 950 cGy total body irradiation (TBI) from a Cesium source
(Nordion, ON, Canada) and transplanted with 500 HSCs 	 30,000 FC
populations by tail vein injection 6 h after irradiation (14). In the allogeneic
model, recipients conditioned with 950 cGy TBI were transplanted with 5,000
HSCs 	 30,000 FL-PB FCs (4).
Colony-forming cell assay. HSCs were cultured at a 1:2 ratio with or without
FCs in methylcellulose containing mouse growth factors (MethoCult GF
M3434; StemCell Technologies, Vancouver, BC, Canada) in duplicate at 37°C
in 5% CO2 and a humidiﬁed atmosphere (13). After 14 days, colonies
containing more than 50 cells were scored.
Chimerism testing. Engraftment of donor cells was evaluated by PBL typing
using three-color ﬂow cytometry, as previously described (15).
FC morphology. Wright-Giemsa staining was performed on cytospins of
100,000 FCs after being ﬁxed in methanol. Slides were examined for dendritic
morphology under optical microscopy.
Statistical analysis. Experimental data were evaluated for signiﬁcant differ-
ences using Student’s t test; P 
 0.05 was considered signiﬁcant. Graft survival
was calculated according to the Kaplan-Meier method (4).
RESULTS
NOD FCs exhibit speciﬁc and signiﬁcant differences
in subpopulations compared with normal controls. In
normal mice, the CD8
/TCR
 FC (FC total) population is
heterogeneous, with the dominant subpopulation pheno-
typically resembling p-preDC (B220
/CD11c
/CD11b
)
(4). Smaller percentages of B-cell (CD19
), NK cell
(NK1.1
DX5
), granulocyte (Gr-1
), and monocyte
(CD14
) subpopulations are also present in FC total from
normal mice (4). We found that NOD and NOR FCs are
comprised of similar distinct heterogeneous subpopula-
tions (Fig. 1A and C) and show a heterogeneous mor-
phology with Wright-Giemsa staining under light
microscopy (Fig. 1B and D). p-preDC FCs represent the
major CD8
/TCR
 FC subpopulation in all strains (female
and male NOD mice, female NOR mice, and male B6 mice)
examined (Fig. 1E). The B220
/CD11c
 FC population in
female and male NOD mice is signiﬁcantly increased
compared with control NOR or B6 mice (Fig. 1H; P 

0.05). The B220
/CD11c
/CD11b
 subset is signiﬁcantly
decreased compared with NOR mice (Fig. 1F; P 
 0.007).
As previously shown, the dominant cell population in
CD19
 FC is pre–B-cells (B220
/CD11c
/intracytoplasmic
IgM
) (4). Of the female NOD FCs, 14% were CD19
,
which is signiﬁcantly decreased compared with NOR and
B6 mice (Fig. 1I, P 
 0.05). Approximately 0.27% of NOD
FCs are CD19
/CD11c
/B220
 cells (Fig. 1G), which is not
signiﬁcantly different than the control strain. DCs with a
similar phenotype from normal LN and spleen have been
shown to function as p-preDC (16). Of the female NOD FC
total, B220
/NK1.1
DX5
 and B220
/Gr-1
 populations
were signiﬁcantly decreased compared with B6 FCs
(Fig. 1K and J). The B220
/CD14
 population was not
signiﬁcantly different in all strains examined (Fig. 1L).
FCs produce cytokines and upregulate activation
markers after stimulation. We evaluated whether NOD
FCs resemble NOR FCs in response to CpG-ODN stimula-
tion. CD86 was upregulated on NOR FCs, whereas CD80
and class II expression was similar in the absence of CPG
stimulation (Fig. 2A and B). However, whereas CD86 was
upregulated on NOD FCs, CD80 expression was markedly
decreased with stimulation (Fig. 2A and B). After CpG-
ODN stimulation, the majority of NOR FCs were in a more
activated state compared with NOD FCs, as evidenced by
their dendritic morphology (Fig. 2C, right panel). In
contrast, NOD FCs did not exhibit a mature morphology
after CpG treatment (Fig. 2C, left panel).
We also examined chemokine and cytokine production
by NOD and NOR p-preDC FCs after CpG-ODN stimula-
tion. In the presence of CpG-ODN, p-preDC FCs produced
more MIP-1/CCL3, RANTES/CCL5, interferon-–induced
protein (IP)-10, IL-6, and TNF- compared with the level of
those in absence of stimulation (Fig. 2D). Notably, p-
preDC FCs from NOR mice produced higher amounts of
IL-6 (5), RANTES/CCL5 (3.5), MIP-1/CCL3 (2.1),
and TNF- (1.9) compared with NOD p-preDC FCs (Fig.
2D). In addition, we found that NOR p-preDC FCs produce
GM-CSF more efﬁciently in response to CpG-ODN stimu-
lation, whereas NOD p-preDC FCs do not (Fig. 2D). Taken
together, these data demonstrate that NOD p-preDC FCs
are impaired in their ability to produce chemokines and
cytokines after CpG-ODN stimulation.
NOD CD8
/TCR
 FC function is signiﬁcantly im-
paired in vivo. We next examined the ability of NOD FCs
to facilitate HSC engraftment using a syngeneic model
(13,14). NOD recipients were ablatively conditioned with
950 cGy TBI and reconstituted with 500 HSCs 	 30,000
FCs sorted from NOD donors. Only 4 of 13 (31%) recipients
of HSCs plus FCs and 4 of 17 (24%) recipients of HSCs
engrafted survived up to 130 days (Fig. 3B). In striking
contrast with normal controls (4), NOD FCs did not
improve HSC engraftment in NOD recipients, as evidenced
by the similar engraftment of HSCs with FCs compared
with the HSCs alone (P  0.579).
We then examined the function of NOR FCs. NOR mice
are MHC-congenic to NOD mice, but do not develop
diabetes (Fig. 3A) (5). Five (31%) of 16 recipients of HSCs
alone engrafted and survived up to 130 days. In contrast,
Y. HUANG AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 236170% (7 of 10) of recipients of HSCs plus FCs engrafted long
term with survival over 130 days (Fig. 3C). Therefore, NOR
FCs signiﬁcantly enhance engraftment of HSCs in limiting
numbers of HSCs (P  0.029).
To assess whether NOR FCs facilitate engraftment of
NOD HSCs, 500 NOD HSCs plus 30,000 NOR FCs (n  15)
were transplanted into NOD recipients conditioned with
950 cGy. All recipients of HSCs alone expired before 130
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FIG. 1. NOD FC total is a heterogeneous population. A and C: CD8
/TCR
 FCs were sorted from NOD bone marrow, blocked using the anti-Fc
receptor Abs and stained with anti-B220, anti-CD19, anti-CD11b, anti-NK1.1, anti-DX5, anti-Gr-1, and anti-CD14 mAbs. Flow cytometric proﬁles
are representative of at least three experiments in NOD or NOR mice. B and D: Morphology of sorted NOD or NOR CD8
/TCR
 FCs were examined
after Wright-Giemsa staining with optical microscopy. E–L: Comparison of phenotype of FCs from NOD, NOR, and B6 bone marrow. Represented
are the means  SD of three independent experiments. *P < 0.05; **P < 0.007.
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the majority of (11 of 21) animals transplanted with NOD
HSCs and NOR FCs survived over 130 days, demonstrating
that NOR FCs also facilitate engraftment of NOD HSCs
(Fig. 3D). As expected, NOD FCs did not enhance engraft-
ment of NOR HSCs (n  16; Fig. 3E).
NOD CD8
/TCR
 FCs failed to promote generation
of colonies from HSCs. To evaluate the function of NOD
FCs in vitro, we tested them using the CFC assay, which
enumerates the number of mono-lineage and multi-lineage
colonies generated by HSCs (13). NOR HSCs cocultured
with NOR FCs for 18 h, then cultured in methylcellulose
for 14 days, generated signiﬁcantly more colonies com-
pared with NOR HSCs alone (n  3; P  0.011; Fig. 4B). In
contrast, NOD FCs failed to enhance colony formation
when cultured with NOD HSCs (n  3; P  0.422; Fig. 4C).
Figure 4A shows representative appearance of CFC-GM
and CFC–granulocyte-erythroid-macrophage-megakaryo-
cyte (GEMM) for NOD HSC. FCs alone did not generate
colonies (Fig. 4B and C).
Removal of CD19
 or NK1.1
DX5
 cells from FCs
does not signiﬁcantly impair facilitation. To deﬁne the
function of CD19
 or NK1.1
DX5
 FC subpopulations,
HSCs, CD8
/TCR
,o rC D 8
/TCR
/CD19
 cells were
sorted from NOR mice and tested in the syngeneic assay
for in vivo facilitation (Fig. 5A). Four of nine (44%)
recipients of HSCs plus CD8
/TCR
/CD19
 FCs exhibited
long-term engraftment and survived at least 110 days (Fig.
5B). Five of eight (63%) animals given HSC  CD8
/TCR

FCs survived up to 110 days (Fig. 5B). There was no
signiﬁcant difference in survival between the HSC plus FC
total group compared with the HSC plus FC, from which
CD19
 FCs had been depleted (P  0.49). Four of 17 (23%)
of recipients transplanted with HSC alone survived up to
110 days (Fig. 5B). These data suggest that the CD19

subpopulation may not play an important role in facilita-
tion and therefore that the low numbers of these cells was
not the cause of ineffective facilitation by NOD FCs.
We next evaluated the contribution of the NK1.1
DX5

FC subpopulation to total FC function. Donor NK cells
have the potential to promote HSC engraftment and sup-
press GVHD in allogeneic transplantation (17). Our previ-
ous data showed that 4–6% of FCs are NK1.1
DX5

cells (4). In NOD mice, 1–1.5% of FCs express
NK1.1
DX5
. To test the contribution of the NK1.1
DX5

FC subpopulation to FC function, HSCs, CD8
/TCR
 FCs,
and CD8
/TCR
/NK1.1
DX5
 cells were sorted from the
marrow of B6 donors; 58% (7/12) of recipients of HSC plus
CD8
/TCR
 FCs survived up to 110 days, and 42% (5/12) of
HSC plus CD8
/TCR
/NK1.1
DX5
 recipients survived
over 110 days (Fig. 5C). Survival of both groups was
signiﬁcantly enhanced compared with the group that re-
ceived HSCs alone (P  0.009).
FL-mobilized NOD FCs facilitate HSC engraftment in
allogeneic recipients. We previously reported that FL
treatment of NOD mice restored production of defective
mature myeloid DCs and plasmacytoid DCs in spleen and
pancreatic lymph nodes and signiﬁcantly increased Treg in
pancreatic lymph nodes (18). This was associated with a
signiﬁcant delay in diabetes progression. To test whether
FL treatment can restore the function of NOD FCs, we
evaluated the phenotype and function of FL-PB FCs. NOD
mice were treated with FL for 10 days. FCs were sorted
from peripheral blood, and sorted FCs were stained with
B220, CD11c, CD19, NK1.1DX5, and CD11b mAbs. There
was a signiﬁcant increase in B220
/CD11c
/CD11b
 DC
and NK1.1
DX5
 subpopulations in FL-PB FCs (Fig. 6A).
The percentage of CD19
 FCs and p-preDC FCs remained
at the same levels as untreated NOD bone marrow FCs
(Fig. 6A).
We next evaluated whether FL treatment can restore
the facilitating function of NOD FCs. FL mobilized NOD
PB FCs were in a more activated state than untreated
NOD bone marrow FCs, as evidenced by their dendritic
morphology (Figs. 6B and 1B). To test function of FL-PB
FCs, HSCs were sorted from bone marrow of untreated
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FIG. 1. Continued.
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Conditioned B10 recipients received 5,000 HSCs plus
30,000 FL-PB FCs. Control mice were transplanted with
5,000 HSCs 	 30,000 FCs from bone marrow of un-
treated NOD mice. FL-PB FCs signiﬁcantly enhanced
engraftment of HSCs, as evidenced by 63% of recipients
(n  8) that received HSC plus FL-PB FCs surviving 120
days (Fig. 6C). A total of 13% and 20% of recipients of
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the percent of CD8
/TCR
 FC total from three separate experiments. C: The morphology of FCs was examined using Wright-Giemsa staining
under optical microscopy after CpG-ODN stimulation. D: p-preDC FCs were cultured with CpG-ODN or medium only. Culture cell-free
supernatants were collected after 18 h and MIP-1/CCL3, RANTES/CCL5, IP-10, IL-6, GM-CSF, and TNF- were measured by LINCO plex
multiplex immunoassay. Data showed an average of two separate experiments.
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untreated NOD mice survived over 120 days, respec-
tively (Fig. 6C).
To conﬁrm that recipients of HSCs plus FL-PB FCs
exhibited durable engraftment and multi-lineage reconsti-
tution, animals were followed for 
4 months. Three-color
ﬂow cytometric analysis was performed. Recipients of
HSCs alone showed the presence of cells of donor origin
including DCs (CD11c), macrophage (Mac-1) and granulo-
cytes (Gr-1), and NK cells (NK1.1DX5) and the presence of
low levels of T-cells (CD8, CD4, -TCR   -TCR) and
B-cells (B220) (Fig. 6D). In contrast, recipients of HSCs
plus FL-PB FCs showed donor chimerism for multi-lin-
eages, including T-cells, B-cells, NK cells, macrophages,
and granulocytes (Fig. 6E).
DISCUSSION
CD8
/TCR
 FCs play an important role in facilitating
engraftment of syngeneic and allogeneic HSCs (1,14,19).
CD8
/TCR
 FCs (FC total) are heterogeneous, including
the following phenotypic subpopulations: p-preDC, B-
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DIABETES, VOL. 57, SEPTEMBER 2008 2365cells, NK cells, and monocytes (4). The p-preDC FC
subpopulation represents the majority of FCs and plays a
critical role in this complex network (4). Removal of the
p-preDC component from the FCs results in complete loss
of facilitation, conﬁrming that p-preDCs are the primary
component in facilitation (4). However, p-preDC FCs
facilitate HSC engraftment signiﬁcantly less efﬁciently
than total FCs (4), suggesting that other FC subpopula-
tions expressing the B-cell and NK cell phenotypes may
play a collaborative role in facilitation. FCs induce gener-
ation of Treg in vitro and in vivo (20,21). More recently, Treg
have been shown to enhance engraftment of HSCs in
syngeneic recipients (22). The fact that the FC maintains
its tolerogenic function in vivo addresses one of the major
concerns regarding DC-based therapies: how to avoid
immune activation and maintain tolerogenicity after infu-
sion in vivo (23). As such, FCs may offer a novel cell-based
therapeutic approach to induce tolerance in the clinic for
treatment of autoimmune disorders.
In the present study, we evaluated the function of FCs in
the context of a mouse model for type 1 diabetes, a
systemic autoimmune disease (5). We found that NOD
FCs, as a heterogeneous population, share phenotypic
characteristics similar to those previously described for
wild-type FCs (4). However, the percentages of both
CD19
 and NK1.1
DX5
 cells in NOD FCs were signiﬁ-
cantly decreased compared with NOR or B6 FCs. NOD
FCs were functionally impaired and failed to facilitate
engraftment of HSCs in both syngeneic and allogeneic
recipients, as well as in an in vitro assay for FCs. Notably,
FL treatment expanded PB FCs in NOD mice and restored
the ability of NOD FCs from the PB to facilitate engraft-
ment of allogeneic HSCs. We propose that the defective
function of NOD FCs may be due to an abnormal activa-
tion status of the p-preDC FC subpopulation or the pres-
ence of impaired function of a collaborative subpopulation
in FCs such as B-cells or NK cells. This hypothesis offers
an attractive explanation for the mechanism by which FCs
enhance HSC engraftment in vivo and induce tolerance.
The majority of FCs are B220
/CD11c
/CD11b
 and
share characteristic features of p-preDC, including mor-
phology and phenotype, secretion of similar cytokines and
chemokines, and maturation after stimulation with CpG-
ODN (4). However, their distinct differences, including the
fact that FCs produce IL-10 whereas p-preDC do not, may
offer an understanding as to how p-preDC FCs remain
tolerogenic in vivo. p-preDCs play an important role in
regulating innate and adaptive immune responses. They
selectively express toll-like receptors (TLR)-7 and TLR-9
and are specialized in rapid secretion of type 1 IFN after
viral stimulation (24). p-preDC can promote the function
of NK cells, B-cells, T-cells, and myeloid DCs through type
1 IFN during an antiviral immune response and differenti-
ate into unique types of mature DCs, which directly
regulate the function of T-cells and thus link innate and
adaptive immune responses. We were the ﬁrst to show that
p-preDC have the potential to facilitate engraftment of
HSCs (4). p-preDCs also induce tolerance to heart allo-
grafts (25). Several studies have demonstrated an associ-
ation between the pathogenesis of autoimmune diseases
(systemic lupus erythematosus, Sjogren’s Syndrome, and
dermatomyositis) and defective function of IFN- produc-
ing p-preDC (26–28). NOD mice exhibit an abnormal DC
phenotype and function (10,11). We show here for the ﬁrst
time that FCs from NOD mice exhibit a functional defect
in facilitating HSC engraftment in vivo and impaired
function in vitro as well. However, the fact that FL
treatment of NOD donors results in production of func-
tional FCs implies that the defect is probably not cell
intrinsic, but rather due to a lacking signal or activated
state.
FL plays a critical role in the development of p-preDC in
humans and mice (29,30). The ability of FL to promote
p-preDC development in vivo was conﬁrmed by experi-
ments showing that administration of FL into human
volunteers led to an increase in the number of PB p-
preDCs in humans and that FL transgenic mice have
increased numbers of p-preDCs, where FL-deﬁcient mice
have fewer p-preDCs (31). Our own work showed that
treatment of prediabetic NOD mice with FL signiﬁcantly
decreased insulitis and progression to diabetes and was
associated with a signiﬁcant increase in myeloid DCs,
plasmacytoid DCs, and Treg (18). When DCs from NOD
mice bone marrow are treated with nuclear factor B–
speciﬁc ODN in vitro, administration of DCs into NOD
mice can effectively prevent the onset of diabetes (32). FL
is also a key cytokine for FC generation and expansion, as
evidenced by FL–bone marrow culture and the mobiliza-
tion of FC in peripheral blood (4). FL-mobilized PB FCs
promote the establishment of donor chimerism and toler-
ance induction. In the present study, we showed that FL
treatment can restore the function of NOD FCs, demon-
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FIG. 4. NOD FCs fail to promote HSC colony formation in vitro. CFC assays were performed on sorted HSCs plus FCs from NOD or NOR mice.
A: Representative appearance of colonies at 14 days. B: HSCs (2,000) and FCs (4,000) were sorted from bone marrow of NOR mice; results are
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tion of FCs in NOD mice.
The importance of myeloid DCs on their ability to
trigger B-cell growth and differentiation has been ad-
dressed (33). A recent study showed that the p-preDCs
regulate B-cell function by producing IFN- and IL-6,
which thereby induces B-cell differentiation (34). Deple-
tion of p-preDC from human blood mononuclear cells
abrogates the secretion of immunoglobulins in response to
inﬂuenza virus and affects the differentiation of activated
B-cells into plasma cells through the secretion of IFN-
and IL-6 (34). Several experimental models in animals
have shown that B-cells are involved in inducing T-cell
tolerance in vivo (35,36). The role of B-cells in autoim-
mune diseases may occur through several mechanistic
pathways that include self-reactive antibodies, secretion
of inﬂammatory cytokines, participation in antigen presen-
tation, and augmentation of T-cell activation (37). In NOD
mice, the B-cell subpopulation (CD19
) within the total
FC population is present at a much lower frequency
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FIG. 5. Removal of CD19
 or NK1.1
DX5
 FC
subpopulations did not signiﬁcantly affect fa-
cilitation. A: BM cells were stained with anti-
CD8 PE or APC, anti–TCR- FITC, anti–
TCR- FITC, and anti-CD19 APC, or anti-
NK1.1DX5 PE, and gated R2 for CD8
/TCR

FCs (middle panel), and CD8
/TCR
CD19
 or
CD8
/TCR
NK1.1
DX5
 subpopulation was
sorted (left panel). B: Survival of syngeneic
recipients transplanted with HSCs and CD8
/
TCR
 FCs or CD8
/TCR
CD19
 NOR recipi-
ents were conditioned with 950 cGy TBI and
transplanted with 500 HSCs alone or in com-
bination with 30,000 CD8
/TCR
 FCs (HSC 
FC group), CD8
/TCR
CD19
 (HSC  CD8
/
TCR
CD19
 group). C: Survival of recipients
transplanted with HSC plus CD8
/TCR
 FCs
or CD8
/TCR
NK1.1
DX5
 in an allogeneic
model (B6 3 C3H). Results are from three to
four separate transplant experiments.
Y. HUANG AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2367compared with NOR and B6 controls. The function of the
CD19
 FC subpopulation remains elusive. Removal of this
subpopulation from normal donors did not impair facilita-
tion. It is formally possible that the CD19
 FC subpopula-
tion does not contribute to FC function or that there is
redundancy in the system that is contributed from another
FC collaborative subpopulation.
NOD FCs also contain signiﬁcantly lower numbers of
NK1.1
DX5
 cells compared with B6 or NOR mice. It was
unclear whether the failure of FC function was due to
decreased numbers of the NK FC subpopulation. NK cells
have been shown to play a major role in regulating early
engraftment of allogeneic bone marrow cells, both by
activation as well as inhibition of immune responses (38).
Adoptive transfer of activated NK cells early after trans-
plantation inhibits GVHD and promotes graft-versus-tumor
(GVT) in the mouse model (39). Recently, various studies
have investigated the interaction between NK cells and
plasmacytoid DCs, suggesting that the cross-talk between
NK cells and DCs leads to NK cell activation and DC
maturation (40). NOD mice exhibit an abnormally low
level of NK cell activity (7,41) and a defect in NK/T-cells
(42). To evaluate whether NK FCs were involved in
facilitation of HSC engraftment, we performed allogeneic
HSC transplantation (B6 3 C3H) using FCs depleted of
the NK FC subpopulation. There was no difference in
engraftment in mice that receive HSC plus FC total vs. FCs
depleted of NK FCs, suggesting that NK FCs did not
contribute to facilitation.
The interaction of DCs and Treg in the regulation of
innate and adaptive immune responses has been reported
(43). The consequences of DC interactions with Treg
depend on the phenotype and maturation status of DCs.
Mature DCs have the unique ability to promote natural Treg
expansion, which limits immune responses to self-antigen
(43,44), whereas immature DCs induce the generation of
adaptive Treg, which control the immune response to
non–self-antigen (45). Mice lacking CD28 or its ligands
have decreased numbers of CD4
/CD25
 cells (46). These
data suggest that both CD86 and CD80 are capable of
delivering the signals that promote Treg generation. It has
been shown that on the NOD mouse background, genetic
ablation of CD86 results in only a subtle decrease in Treg
numbers (20–30% reduction). The remaining Treg were
largely dependent on CD80, as the additional injection of
anti-CD80 blocking mAbs substantially decreased the
number of CD4
/CD25
 cells (70% reduction). These
data support a more important role for CD80 than CD86 in
generation of Treg (47). Notably, we found that NOD FCs
exhibit signiﬁcantly impaired upregulation of CD86 after
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FIG. 6. FL-mobilized PB FCs facilitate HSC engraftment in allogeneic recipients. Recombinant human FL (expressed from CHO cells) (provided
by Amgen, Thousand Oaks, CA) was diluted in 0.1% mouse serum albumin (MSA; Sigma, St. Louis, MO) at a concentration of 100 g/ml. Donor
NOD female mice were injected with 10 g FL once daily subcutaneously from day 0 to day 9. Control mice received saline injections. A: Flow
cytometric analysis of subpopulations in sorted FL-mobilized PB FCs. B: Sorted FL-PB FCs were examined after Wright-Giemsa staining by
optical microscopy. C: Survival of recipients of HSC plus FL-mobilized PB FCs in allogeneic model (NOD 3 B10). B10 recipients were conditioned
with 950 cGy TBI and transplanted with 10,000 HSCs from untreated NOD donors either alone or mixed with 30,000 puriﬁed FCs from untreated
NOD bone marrow, or from FL-mobilized PB FCs from NOD mice. D and E: Multilineage typing of representative B10 recipients of NOD HSCs
alone or recipients of NOD HSCs plus FL-PB FCs. Multilineage data are from PB 3 months after transplantation and analyzed based on the
lymphoid and myeloid gate. Data shown are from one representative recipient. A total of three to ﬁve recipients were analyzed per group.
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from diabetes-resistant donors, they failed to produce
GM-CSF and produced signiﬁcantly lower levels of IL-6
after CpG stimulation. Several groups have reported that
NOD mice exhibited reduced Treg frequency (48,49), and
their impaired suppressive function has been linked to
diabetes pathogenesis (50). The fact that wild-type FCs
can induce the generation of Treg, but only in the presence
of CpG-ODN (21), and that they are impaired in function in
diabetes-prone NOD mice suggests that FCs may also play
a distinct role in diabetes pathogenesis.
In conclusion, our data reveal a novel defect in NOD FC
function that is restored by treatment with FL. Our data
suggest the critical role of FL in developing and maintain-
ing the function of FCs. These ﬁndings may have clinical
implications for the treatment of type 1 diabetes and
possibly other autoimmune disease states.
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